GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

GSK has licensed its experimental Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL) for further development and distribution, particularly targeting low and middle-income regions1234.

Bharat Biotech will assume responsibility for the continued clinical development (including Phase 3 trials), regulatory approvals, and large-scale manufacturing of the vaccine25.

The vaccine candidate altSonflex1-2-3 is designed for broad serotype coverage and is based on the Generalized Modules for Membrane Antigens (GMMA) platform, showing promising early clinical results5.

There is currently no licensed vaccine for Shigellosis, a severe form of bacterial diarrhea that poses a rising health threat due to increasing antimicrobial resistance5.

GSK will continue to support the program through clinical trial design, external funding, and strategy for access, delivery, and commercialization5.

Sources:

1. https://www.worldpharmaceuticals.net/news/gsk-and-bharat-biotech-collaborate-on-shigella-vaccine/

2. https://www.pharmaceutical-technology.com/news/gsk-bharat-biotech/

3. https://www.thepharmaletter.com/pharmaceutical/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech

4. https://www.pharmexec.com/view/gsk-licenses-altsonflex1-2-3-shigella-vaccine-bharat-biotech

5. https://economictimes.com/industry/healthcare/biotech/bharat-biotech-gsk-join-hands-to-develop-vaccine-for-severe-diarrhoea/articleshow/121803810.cms